– USA, MA – Aushon BioSystems, a leading provider of high sensitivity assays, instrumentation and services for multiplex quantitative detection of protein biomarkers, today announced Stan Lapidus, innovative leader in the diagnostic market, has been elected to Aushon’s board of directors.
An acclaimed innovator, entrepreneur and business leader, Lapidus brings more than three decades of experience founding and leading breakthrough diagnostic companies that have significantly improved patients lives. In the late 80’s, he founded Cytyc (now part of Hologic) to pioneer new technology for cervical cancer screening serving as CEO from 1987 through 1994. He founded Exact Sciences (NASDAQ: EXAS), non-invasive, DNA-based tests for colorectal cancer screening in 1995 and served as CEO until 2001 and Chairman until the end of 2005. In addition, Lapidus was both the founder and CEO of SynapDx, an autism early detection company, and Helicos Biosciences.
Lapidus earned a BSEE degree from The Cooper Union for the Advancement of Science and Art. He holds an academic appointment at MIT and is a fellow of the College of the American Institute of Medical and Biological Engineering.
“Stan is one of the most accomplished innovators and leaders in the diagnostics industry, and we are excited to have him join Aushon’s board of directors,” said Susan Vogt, CEO of Aushon. “His experience in guiding companies through all phases of development and growth will be invaluable as we accelerate adoption of our technology platform.”
“Aushon’s technology has demonstrated exciting promise for the early detection of disease using protein biomarkers. The ability to accurately and simultaneously measure multiple proteins with a high degree of sensitivity and precision opens up exciting new opportunities for non-invasive diagnostics and patient monitoring,” said Lapidus. “I look forward to working with Aushon’s board and management team to advance Aushon’s technology platform into these new applications.”
About Aushon BioSystems
Aushon BioSystems, Inc. is leading the way in protein biomarker discovery, development and analysis. Through the unique combination of proprietary microarray printing, extensive biomarker content and ease-of-use, the CiraTM immunoassay platform is serving leading pharmaceutical companies, contract research organizations and clinical reference laboratories worldwide. Our products are used for applications in preclinical and clinical biomarker research accelerating the evaluation of potential drug candidates and advancing the use of biomarker profiles in diagnostics.
For more information : https://www.aushon.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
